Quoin Pharmaceuticals, Ltd.
Data quality: 83%
QNRX
Nasdaq
Manufacturing
Chemicals
$5.65
▼
$0.34
(-5.68%)
Mkt Cap: 10.19 M
Price
$5.65
Mkt Cap
10.19 M
Day Range
$5.50 — $6.17
52-Week Range
$5.01 — $41.80
Volume
28,398
Open $5.96
50D / 200D Avg
$8.12
30.42% below
50D / 200D Avg
$10.07
43.88% below
Quick Summary
Key Takeaways
Negative free cash flow of -13.54 M
Growth
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Quality
Return on Equity
-2364.66%
Below sector avg (-51.02%)
ROICN/A
Net MarginN/A
Op. MarginN/A
Safety
Debt / Equity
N/A
Current Ratio1.04
Interest CoverageN/A
Valuation
PE (TTM)
-0.64
Above sector avg (-1.98)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A
Price History
Financial Trends
Peer Comparison
vs Manufacturing sector median (44 peers)
Peer Comparison
vs Manufacturing sector median (44 peers)| Metric | Stock | Sector Median |
|---|---|---|
| P/E | -0.6 | -2.0 |
| P/B | — | 5.1 |
| ROE % | -2364.7 | -51.0 |
| Net Margin % | — | -150.2 |
| Rev Growth 5Y % | — | 9.3 |
| D/E | — | 0.3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | N/A | Net Income (TTM) | -15.80 M |
| ROE | -2364.66% | ROA | -206.11% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -13.54 M |
| ROIC | N/A | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 1.04 |
| Interest Coverage | N/A | Asset Turnover | N/A |
| Working Capital | 250,779 | Tangible Book Value | -1.62 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -0.64 | Forward P/E | N/A |
| P/B Ratio | N/A | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -132.88% | ||
| Market Cap | 10.19 M | Enterprise Value | 8.36 M |
| Per Share | |||
| EPS (Diluted TTM) | N/A | Revenue / Share | N/A |
| FCF / Share | -7.51 | OCF / Share | -7.51 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 85.68% |
| SBC-Adj. FCF | -14.72 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | 0.0 |
| Net Income | -15.80 M | -8.96 M | -8.69 M | -9.38 M | -21.46 M |
| EPS (Diluted) | — | — | — | — | -0.01 |
| Gross Profit | — | — | — | — | — |
| Operating Income | — | — | — | — | — |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 9.80 M | 3.60 M | 3.31 M | 2.67 M | 1.56 M |
| SG&A Expenses | 6.49 M | 5.93 M | 6.07 M | 6.58 M | 4.50 M |
| D&A | — | — | — | — | — |
| Interest Expense | — | — | — | — | 1.09 M |
| Income Tax | — | — | — | — | — |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 20.39 M | 15.71 M | 12.17 M | 14.46 M | 9.36 M |
| Total Liabilities | 7.27 M | 6.50 M | 6.51 M | 7.05 M | 8.70 M |
| Shareholders' Equity | 13.12 M | 9.20 M | 5.66 M | 7.41 M | 657,032.0 |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 3.82 M | 3.62 M | 2.40 M | 2.86 M | 7.48 M |
| Current Assets | 20.01 M | 14.93 M | 11.29 M | 13.37 M | 8.50 M |
| Current Liabilities | 5.55 M | 4.18 M | 3.58 M | 3.53 M | — |
{"event":"ticker_viewed","properties":{"ticker":"QNRX","listing_kind":"stock","pathname":"/stocks/qnrx","exchange":"Nasdaq","country":"US"}}